These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 12682628

  • 1. HLA-DR antigen-negative acute myeloid leukemia.
    Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR.
    Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of acute myeloid leukemia without HLA-DR expression.
    Moon H, Lee S, Huh J, Chung WS.
    Korean J Lab Med; 2007 Oct; 27(5):313-7. PubMed ID: 18094594
    [Abstract] [Full Text] [Related]

  • 3. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
    Ferrari A, Bussaglia E, Úbeda J, Facchini L, Aventin A, Sierra J, Nomdedéu JF.
    Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
    [Abstract] [Full Text] [Related]

  • 4. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, Stamatoullas A, Monconduit M, Tilly H.
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Li L, Schmitt A, Reinhardt P, Greiner J, Ringhoffer M, Vaida B, Bommer M, Vollmer M, Wiesneth M, Döhner H, Schmitt M.
    Cancer Immun; 2003 Jul 16; 3():8. PubMed ID: 12862419
    [Abstract] [Full Text] [Related]

  • 8. [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
    Sun HM, Qian SX, Wu YJ, Qiao C, Hong M, Fan L, Yang H, Zhang JF, Zhang SJ, Wu HX, Qiu HX, Lu H, Xu W, Sheng RL, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb 16; 17(1):176-9. PubMed ID: 19236773
    [Abstract] [Full Text] [Related]

  • 9. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.
    Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsky MA, Johnson LR, White G.
    Arch Pathol Lab Med; 2003 Jan 16; 127(1):42-8. PubMed ID: 12521365
    [Abstract] [Full Text] [Related]

  • 10. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
    Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ.
    Cancer Res; 2004 Aug 15; 64(16):5546-50. PubMed ID: 15313888
    [Abstract] [Full Text] [Related]

  • 11. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
    Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadié M, Béné MC.
    Leukemia; 2003 Mar 15; 17(3):515-27. PubMed ID: 12646939
    [Abstract] [Full Text] [Related]

  • 12. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
    Cascavilla N, Musto P, D'Arena G, Melillo L, Carella AM, Petrilli MP, Sanpaolo G, Carotenuto M.
    Haematologica; 1998 May 15; 83(5):392-7. PubMed ID: 9658721
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
    Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G.
    Leukemia; 1994 Mar 15; 8(3):388-94. PubMed ID: 7907393
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K, AML Study Group.
    Haematologica; 2005 Dec 15; 90(12):1626-34. PubMed ID: 16330435
    [Abstract] [Full Text] [Related]

  • 17. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
    Lewis RE, Cruse JM, Webb RN, Sanders CM, Beason K.
    Exp Mol Pathol; 2007 Oct 15; 83(2):269-73. PubMed ID: 17603036
    [Abstract] [Full Text] [Related]

  • 18. [Clinicopathological features in HLA-DR-negative acute myeloid leukemia].
    Muroi K, Yoshida M, Suzuki T, Amemiya Y, Hatake K, Miura Y.
    Rinsho Ketsueki; 1997 Aug 15; 38(8):631-7. PubMed ID: 9311267
    [Abstract] [Full Text] [Related]

  • 19. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities.
    Dong HY, Kung JX, Bhardwaj V, McGill J.
    Am J Clin Pathol; 2011 Jan 15; 135(1):76-84. PubMed ID: 21173127
    [Abstract] [Full Text] [Related]

  • 20. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C, Eisterer W, Hilbe W, Gotwald M, Hofmann J, Zabernigg A, Cianfriglia M, Thaler J.
    Leukemia; 1995 Feb 15; 9(2):350-6. PubMed ID: 7869774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.